- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05924620
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: a Randomized, Controlled Trial
Study Overview
Detailed Description
This is a prospective and randomized study involving patients with primary aldosteronism(PA). All paticipants will be randomized into finerenone group(Intervention group) and spironolactone group(Control group) and to compare the antihypertensive effect in patients with PA.
If the self-measured blood pressure of patients at home continues to be greater than 140/90 mmHg at 2-4 weeks, spironolactone or finerenone should be increased to 40mg qd, and electrolytes should be reviewed at 2 weeks after dosed.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Qifu Q Li, PhD
- Phone Number: +86 023-89011552
- Email: liqifu@yeah.net
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400016
- Recruiting
- The First Affilated Hospital of Chongqing Medical University
-
Contact:
- Qifu Q Li, PhD
- Phone Number: +862389011552
- Email: liqifu@yeah.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria: Patients who meet the following criterion can be included in this study.
- Patients know the whole process of the trial and voluntarily accepted randomization, intervention and follow-up.
- Patients voluntarily participated in the study and signed an informed consent, willing to complete all follow-up visits as required.
- Aged between 18-70, male or female, with legal capacity.
- eGFR≥60(ml/min/1.73 m2)
- Patients with PA and substandard blood pressure (≥140/90mmHg) who didn't take any antihypertensive drugs or who had been using antihypertensive drugs other than MRA steadily for 2 weeks or more
Exclusion Criteria: Patients with one of the following conditions will be excluded in this study:
- To assess patients with poor compliance who had difficulty fully participating in the study, or who refused to sign written informed consent for the study
- Patients with heart failure (New York Heart Association (NYHA) class III or IV), liver transaminase levels were more than 2 times higher than the upper limit of normal, estimated glomerulus filtration rate<30ml/min/m2
- Patients with serum potassium > 5.0mmol/L without potassium supplementation
- Patients with stroke or acute coronary syndrome within 3 months
- Pregnant or lactating women
- Patients currently receiving sex hormone or glucocorticoid therapy
- Patients with a history of uncontrolled malignant tumor
- Patients who took MRA within 2 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with PA using finerenone
Patients with PA divided into this group need to take finerenone for 60 days (20mg qd)
|
Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
Other Names:
|
No Intervention: Patients with PA using spironolactone
Patients with PA divided into this group need to take spironolactone for 60 days (20mg qd)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the change of daytime mean systolic blood pressure in the overall cohort between two groups.
Time Frame: At baseline and 2 month of follow-up
|
Measured by ambulatory blood pressure monitoring
|
At baseline and 2 month of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the serum potassium elevation in the overall cohort between two groups.
Time Frame: At baseline and 2 month of follow-up
|
Measured by blood electrolytes
|
At baseline and 2 month of follow-up
|
Compare the change of daytime mean diastolic blood pressure in the overall cohort between two groups.
Time Frame: At baseline and 2 month of follow-up
|
Measured by ambulatory blood pressure monitoring
|
At baseline and 2 month of follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Qifu Q Li, PhD, the Chongqing Primary Aldosteronism Study (CONPASS) Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Finerenone study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Aldosteronism
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
Qifu LiWest China Hospital; Tongji Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsRecruitingPrimary AldosteronismChina
-
Xiao ChenRecruitingPrimary AldosteronismChina
-
Liverpool University Hospitals NHS Foundation TrustRecruiting
-
The Cleveland ClinicRecruitingPrimary AldosteronismUnited States
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Hypertension CanadaRecruitingPrimary AldosteronismCanada
-
AstraZenecaActive, not recruitingPrimary Aldosteronism | HyperaldosteronismUnited States
-
Chongqing Medical UniversityCompletedPrimary AldosteronismChina
-
Qifu LiThe Affiliated Hospital Of Southwest Medical UniversityCompletedPrimary AldosteronismChina
-
Chongqing Medical UniversityCompletedPrimary AldosteronismChina
Clinical Trials on finerenone
-
Colorado Prevention CenterBayer; Saint Luke's Hospital of Kansas CityRecruitingHeart Failure | Acute Heart FailureUnited States
-
BayerActive, not recruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
Saga UniversityActive, not recruitingChronic Kidney Diseases | Type 2 DiabetesJapan
-
BayerActive, not recruitingNon-diabetic Chronic Kidney DiseaseHong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
-
BayerCompletedChronic Kidney Disease | Worsening Chronic Heart FailureGermany
-
BayerCompletedPharmacokineticsGermany
-
BayerRecruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseIndia
-
BayerRecruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
-
BayerCompletedChronic Kidney DiseaseBelgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
-
BayerCompletedDiabetic RetinopathyUnited Kingdom, Bulgaria